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Objective: Associations of glycated hemoglobin A1c (HbA1c) levels to incident coronary and cardiovas-
cular events among non-diabetic patients with coronary artery disease are unclear. We investigated
relations of HbA1c to long-term prognosis in such patients.
Methods: A prospective cohort of 2519 patients undergoing elective coronary angiography for suspected
stable angina pectoris (SAP) was divided into pre-deﬁned categories according to HbA1c (%) levels (<5.0,
5.0e5.6 (reference), 5.7e6.4), and followed for median 4.9 years. The primary end-point was major
coronary events (including non-fatal and fatal acute myocardial infarctions, and sudden cardiac death).
Secondary end-points were death from cardiovascular disease (CVD) and all-cause mortality. Hazard
ratios (HRs) (95% conﬁdence intervals [CIs]) were obtained by Cox regression.
Results: Median age at inclusion was 62 years, 73% were males, median HbA1c was 5.6% and random
plasma-glucose 5.4 mmol/L. After multivariate adjustment, HbA1c levels within the pre-diabetic range
were not associated with risk of major coronary events, HR (95% CI): 1.13 (0.79e1.62); P ¼ 0.49, death
from CVD or all-cause mortality HR (95% CI): 0.95 (0.55e1.66) and 1.04 (0.70e1.53), respectively;
P  0.85. Similarly, there was no signiﬁcant association between HbA1c values within the lowest cate-
gory and risk of study outcomes, (P  0.18).
Conclusion: In non-diabetic patients with suspected SAP, there was no overall association between
HbA1c levels and prognosis, questioning an independent role of glycemia in the pathogenesis of
atherosclerotic complications in these patients.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).sease, Haukeland University
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Hemoglobin A1c (HbA1c) is a marker of glycemia, reﬂecting the
average plasma glucose concentration over the previous 8e12
weeks [1]. It has been extensively applied for the monitoring and
control of diabetes mellitus and was recently introduced as a
diagnostic test deﬁning a pre-diabetic state and overt diabetes, at
5.7% and 6.5%, respectively [1].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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doseeresponse relationship between HbA1c and risk of acute
myocardial infarction (AMI), independent of the presence of self-
reported diabetes [2]. Further, elevated HbA1c levels, even within
the pre-diabetic range, have been associated with increased risk of
all-cause mortality and cardiovascular disease (CVD) in general
populations [3,4]. However, it is not established whether the as-
sociations to macrovascular disease reﬂect glucose levels per se, or
is related to the frequent co-occurrence of pre-diabetes with the
metabolic syndrome [5]. Interestingly, low HbA1c levels have also
been associated with increased risk of mortality [4,6], although
results have been inconsistent [7] and underlying mechanisms
remain unknown.
The prognostic implications of HbA1c levels in patients without
diabetes, but with pre-existent coronary artery disease (CAD) have
not been extensively evaluated. Associations of HbA1c to all-cause
mortality have been demonstrated in such patients [8], but it is not
clear whether the unfavorable prognosis is attributable to CVD [9].
We therefore aimed to evaluate the relations of HbA1c levels
with risk of major coronary events, CVD mortality and all-cause
mortality in a large cohort of patients without diabetes, referred
to coronary angiography for suspected stable angina pectoris (SAP).
2. Methods
2.1. Study population
The source population consists of 4164 adults who underwent
elective coronary angiography for suspected SAP in either of two
Norwegian university hospitals between 2000 and 2004 [10]. A
total of 2573 (61.8%) were originally included in the Western Nor-
way B-Vitamin Intervention Trial (WENBIT; ClinicalTrials.gov
Identiﬁer: NCT00354081) [11].
For the present prospective cohort study, 1603 (38.5%) patients
with diabetes, deﬁned according to American Diabetes Association
criteria [1], and 42 (1.0%) patients with missing HbA1c measure-
ments were excluded, leaving 2519 (60.5%) participants eligible for
the ﬁnal analyses.
The study fulﬁlled the Declaration of Helsinki and was approved
by The Regional Committee for Medical and Health Research Ethics
(approval number 2010/1880) and The Norwegian Data Protection
Authority. All participants provided written informed consents.
2.2. Baseline data
Information on medical history, cardiovascular risk factors and
current medication were provided through a self-administered
questionnaire completed by each patient, as previously reported
[11]. Trained study personnel validated completed questionnaires
against medical records. Fasting referred to not having ingested any
food or beverage 6 h prior to blood sampling. Left ventricular
ejection fraction, angiographic extent of CAD and smoking status
was assessed as previously described [10]. Body mass index (BMI)
was calculated by dividing weight by height squared (kg/m2).
2.3. Biochemical analyses
Standard blood laboratory parameters were analyzed in fresh
samples according to routine protocols at the referring hospitals.
Study speciﬁc samples were collected together with routine blood
samples before coronary angiography, and stored at 80 C until
analysis. Reagent kits of type Tina-quant® were used for measure-
ment of apolipoprotein A-I and apolipoprotein B. C-reactive protein
(CRP) (latex, high sensitive assay) were obtained from Roche Di-
agnostics (GmbH, Mannheim, Germany) and serum measurementson these parameters were done on the Hitachi 917 system (Roche
Diagnostics). HbA1c was determined by matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry [12] and
plasma cotinine by liquid chromatography/tandem mass spec-
trometry at BEVITAL AS, Bergen, Norway [13]. We measured serum
cardiac troponin T using a high sensitive cardiac troponin T assay on
Modular E170 (Roche Diagnostics), with 3 ng/L as the lower
detection limit. Cobalamin was measured using a microbiological
assay [14]. Estimated glomerular ﬁltration rate (eGFR) was calcu-
lated using the Chronic Kidney Disease Epidemiology Collaboration
equation [15].
2.4. Follow-up and clinical end-points
Information on study end-points was collected as described
previously [16]. The primary end-point was major coronary events,
which included non-fatal and fatal AMIs, and sudden cardiac death
(diagnoses coded I21, I46 and R96 according to the International
Statistical Classiﬁcation of Diseases, 10th version [ICD-10]). Sec-
ondary end-points were CVD mortality (causes of death coded
I00eI99 according to the ICD-10 system), and all-cause mortality.
Patients were followed up until they experienced an event, or
throughout December 31, 2006.
2.5. Statistical analyses
The total cohort was divided into pre-deﬁned categories ac-
cording to HbA1c levels (%): <5.0, 5.0e5.6 and 5.7e6.4 [17]. Base-
line continuous and categorical variables are listed as median (25th,
75th percentile) and counts (%), respectively. The linear trends
across HbA1c categories were tested by median quantile regression
models [18] for continuous variables and logistic regression for
categorical variables.
The associations betweenHbA1c and risk of study outcomeswere
explored by Cox proportional hazard regression with the HbA1c
range 5.0e5.6% as the reference category. In addition, generalized
additive modeling was performed to assess potential risk associa-
tions on a continuous scale. The simple model included age and sex
as independent variables. Additional covariates for the multivariate
model were selected on the basis of clinical relevance and included:
current smoking (dichotomous), hypertension (dichotomous),
number of signiﬁcantly stenosed coronary arteries (0e3), left ven-
tricular ejection fraction (continuous), revascularization following
angiography (none, percutaneous coronary intervention or coronary
artery bypass graft surgery: 0e1), previous AMI (dichotomous), eGFR
(continuous), CRP (continuous), BMI (continuous), apolipoprotein A-
I (continuous), apolipoprotein B (continuous), and treatment with
statins or aspirin (both dichotomous). Additional adjustments for
circulating levels of hemoglobin, cobalamin, alanine aminotrans-
ferase and aspartate aminotransferase, self-reported weekly alcohol
consumption and use of beta-blockers, angiotensin-converting
enzyme inhibitors or angiotensin receptor-blockers did not appre-
ciably alter the results and were not included in the ﬁnal model. We
performed logelog plots and plotted Schoenfeld residuals [19] to
ensure that the assumption of proportional hazardswas not violated.
Statistical power was assessed on the basis of a two-tailed c2
test comparing an HbA1c of 5.7% versus <5.7% (SamplePower 2.0,
SPSS Inc., Chicago, IL). At a ¼ 0.05, a power of 97% was obtained for
an increase in event rate from 10% to 15% (relative risk 1.5) for the
primary end-point major coronary events.
All probability values are two-tailed, with a 5% signiﬁcance level.
Statistical analyses were performed with R 3.0.2 (The R-Foundation
for Statistical Computing, Vienna, Austria) [20], the R-packages
‘survival’ [21] and ‘quantreg’ [22], and IBM SPSS Statistics 21 (SPSS
IBM, NY, USA).
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3.1. Patient characteristics at baseline
For the total cohort, median (25th, 75th percentile) age was 62
(53, 67) years, 1841 (73%) were men, 809 (32%) were current
smokers and 750 (30%) had previously undergone a coronary artery
revascularization procedure. Median (25th, 75th percentile)
random plasma-glucose was 5.4 (5.0, 6.1) mmol/L, HbA1c 5.6 (5.0,
6.0) % and BMI 26.0 (23.9, 28.4) kg/m2. Baseline characteristics
according to the pre-deﬁned HbA1c categories are shown in Table 1.
As compared to the reference category, the proportion of
women was higher among those having HbA1c levels within
5.7e6.4%, and the frequency of signiﬁcant CAD and triple-vessel
disease was lower. Correspondingly, a smaller proportion
received revascularization therapy following baseline coronary
angiography. Furthermore, trends were observed for lower left
ventricular ejection fraction and less frequent use of aspirin and
statins in the pre-diabetic category.
A total of 295 (11.7%) and 33 (1.3%) patients reported to have
chronic pulmonary disease and cancer, respectively, at baseline,Table 1
Baseline characteristics of the study population (n ¼ 2519) according to HbA1c categorie
HbA1c (%)
<5.0%
n ¼ 637
HbA1c (%) 4.6 (4.2, 4.8)
Age (years) 61 (54, 68)
Males [N (%)] 498 (78.2)
BMI (kg/m2) 26.0 (24.1, 28.1)
Left ventricular ejection fraction (%) 67 (60, 70)
Fasting [N (%)] 141 (22.1)
Random glucose (mmol/L) 5.4 (4.9, 6.0)
Triglycerides (mmol/L) 1.40 (1.09, 2.00)
Apolipoprotein A-I (g/L) 1.32 (1.14, 1.47)
Apolipoprotein B (g/L) 0.89 (0.75, 1.05)
Serum CRP (mg/L) 1.63 (0.79, 3.06)
eGFR (mL/min) 91 (79, 100)
Hgb (g/dL) 14.4 (13.6, 15.2)
ALT (IU/L) 28 (21, 39)
AST (IU/L) 25 (21, 31)
Cobalamin (pmol/L) 352 (273, 444)
Cardiac troponin T 4 (3, 9)
Cardiovascular history and risk factors [N (%)]
Current smoking 212 (33.3)
Previous AMI 260 (40.8)
Previous PCI 138 (21.7)
Previous CABG 75 (11.8)
Hypertension 266 (41.8)
Cancer 5 (0.8)
Chronic pulmonary disease 61 (9.6)
Baseline coronary angiography [N (%)]
No signiﬁcant stenosis 120 (18.8)
One-vessel disease 170 (26.7)
Two-vessel disease 141 (22.1)
Three-vessel disease 206 (32.3)
Baseline coronary intervention [N (%)]
None or medication only 264 (41.4)
PCI 210 (33.0)
CABG 152 (23.9)
Medications at discharge [N (%)]
Statins 530 (83.2)
Aspirin 547 (85.9)
Dual anti-platelet therapya 103 (16.2)
b-blocker 472 (74.1)
ACE inhibitor and/or ARB 161 (25.3)
Abbreviations: HbA1c, glycated hemoglobin A1c; BMI, body mass index; CRP, C-reactive
aminotransferase; AST, aspartate aminotransferase; AMI, acute myocardial infarction; PC
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.
a Dual anti-platelet therapy, any two anti-platelet agents.with no differences in prevalences according to HbA1c levels.
Similarly, median values of BMI, serum triglycerides, cardiac
troponin T, hemoglobin, and aminotransferases showed no sub-
stantial variation across categories of HbA1c (Table 1). Neither were
there any differences in self-reported weekly alcohol consumption
(data not shown), although information on the latter parameter
was only available for 2011 (80%) of the participants.
3.2. Clinical outcomes according to HbA1c levels
During a median (25th, 75th percentile) follow-up of 4.8 (3.7,
5.8) years, 178 (7.1%) patients experienced a major coronary event.
CVD accounted for 75 (3.0%) deaths and 155 (6.2%) participants
died from any cause. The age and gender adjusted relationships
between the pre-deﬁned HbA1c categories and end-points are
shown in Table 2. Compared to the reference category (HbA1c
5.0e5.6%), multivariate hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) for the HbA1c range 5.7e6.4% were 1.13 (0.79e1.62)
for major coronary events, 0.95 (0.55e1.66) for CVD mortality, and
1.04 (0.70e1.53) for all-cause mortality (all P  0.49). Similarly,
there were no signiﬁcant increases in risk of clinical outcomess.
5.0e5.6% 5.7e6.4% P for trend
n ¼ 771 n ¼ 1111
5.4 (5.2, 5.6) 6.1 (5.9, 6.3) e
62 (55, 69) 62 (55, 70) 0.20
556 (72.1) 787 (70.8) 0.002
25.9 (23.7, 28.4) 26.2 (24.0, 28.6) 0.23
65 (60, 70) 66 (60, 70) 0.02
199 (25.8) 303 (27.3) 0.07
5.5 (5.0, 6.1) 5.5 (5.0, 6.1) 0.02
1.46 (1.04, 2.07) 1.46 (1.07, 2.00) 0.27
1.30 (1.15, 1.49) 1.30 (1.14, 1.48) 0.36
0.87 (0.72, 1.06) 0.87 (0.72, 1.04) 0.04
1.65 (0.83, 3.33) 1.71 (0.86, 3.69) 0.39
91 (80, 100) 91 (79, 99) 1.00
14.4 (13.5, 15.1) 14.3 (13.4, 15.0) 0.25
28 (21, 38) 27 (19, 37) 0.26
25 (21, 30) 25 (21, 30) 1.00
358 (269, 445) 363 (274, 468) 0.18
4 (3, 9) 4 (3, 9) 1.00
250 (32.4) 347 (31.2) 0.36
312 (40.5) 420 (37.8) 0.18
137 (17.8) 188 (16.9) 0.02
96 (12.5) 116 (10.4) 0.32
334 (43.3) 513 (46.2) 0.06
10 (1.3) 18 (1.6) 0.15
97 (12.6) 137 (12.3) 0.12
196 (25.4) 316 (28.4) <0.001
189 (24.5) 238 (21.4) 0.01
170 (22.0) 265 (23.9) 0.36
216 (28.0) 292 (26.3) 0.009
355 (46.0) 520 (46.8) 0.04
261 (33.9) 361 (32.5) 0.77
141 (18.3) 209 (18.8) 0.02
620 (80.4) 869 (78.2) 0.01
652 (84.6) 884 (79.6) <0.001
133 (17.3) 151 (13.6) 0.09
577 (74.8) 780 (70.2) 0.05
208 (27.0) 354 (31.9) 0.002
protein; eGFR, estimated glomerular ﬁltration rate; Hgb, hemoglobin; ALT, alanine
I, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery;
Table 2
Risk associations between HbA1c categories and clinical outcomes in the study
population (n ¼ 2519).
End-point HbA1c
category
Events Simple
modela
HR (95% CI)
P Multivariate
modelb
HR (95% CI)
P
Major
coronary
event
5.7e6.4% 79 1.13 (0.79e1.61) 0.50 1.13 (0.79e1.62) 0.49
5.0e5.6% 50 Ref. Ref.
<5.0% 49 1.19 (0.80e1.76) 0.39 1.16 (0.78e1.73) 0.46
CVD
mortality
5.7e6.4% 33 1.09 (0.63e1.88) 0.77 0.95 (0.55e1.66) 0.86
5.0e5.6% 21 Ref. Ref.
<5.0% 21 1.22 (0.67e2.24) 0.51 1.23 (0.66e2.26) 0.52
All-cause
mortality
5.7e6.4% 67 1.11 (0.76e1.64) 0.59 1.04 (0.70e1.53) 0.85
5.0e5.6% 42 Ref. Ref.
<5.0% 46 1.33 (0.88e2.03) 0.18 1.33 (0.87e2.04) 0.18
Abbreviations: HbA1c, glycated hemoglobin A1c; HR, hazard ratio; CI, conﬁdence
interval; CVD, cardiovascular disease.
a Adjusted for age and gender.
b Adjusted for age, gender, current smoking, hypertension, number of signiﬁ-
cantly stenosed coronary arteries (0e3), left ventricular ejection fraction, revascu-
larization following angiography (none, percutaneous coronary intervention or
coronary artery bypass graft surgery), previous acute myocardial infarction, esti-
mated glomerular ﬁltration rate, C-reactive protein, body mass index, apolipopro-
tein A-I, apolipoprotein B, and treatment with statins and aspirin.
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Further, multivariate generalized additive regression, with HbA1c
as a continuous parameter, did not reveal signiﬁcant risk associa-
tions to the primary end-point, major coronary events (P  0.16;
Fig. 1), or the secondary end-points (P  0.20).
In a supplementary analysis, we included the subjects classiﬁed
with diabetes mellitus (n ¼ 1603) at baseline [1] to the study
population. Notably, these patients were at signiﬁcantly increased
risk of major coronary events, as well as CVD e and all-cause
mortality, with similar HRs in age and gender adjusted as in
multivariate analyses (Supplemental Table 1).
4. Discussion
4.1. Principal ﬁndings
In this large cohort of suspected SAP patients without diabetes,
we observed no overall association between HbA1c levels and riskFig. 1. Plasma HbA1c levels and risk of major coronary events in 2519 non-diabetic patients
(HbA1c) levels (%) and risk of major coronary events obtained by generalized additive regr
model (right panel) is additionally adjusted for current smoking, hypertension, number of
cularization following angiography (none, percutaneous coronary intervention or coronary a
ﬁltration rate, C-reactive protein, body mass index, apolipoprotein A-I, apolipoprotein B, and
areas the 95% conﬁdence interval. Density plots show the distribution of HbA1c, and verticof incident coronary events or mortality during nearly 5 years of
follow-up.
4.2. HbA1c levels and disease risk in previous studies
HbA1c correlates with micro- and macrovascular complications
in patients with diabetes [1]. HbA1c >8.0% as compared to <7.0%
have been reported to increase the long-term risk of all-cause
mortality in such patients [23]. On the other hand, intensive
glucose-lowering treatment (target HbA1c <6.0%) has also been
associated with all-cause mortality [24].
In initially healthy populations, elevated HbA1c was associated
with increased risk of all-cause mortality, new onset diabetes and
CVD [3,4,7,25], but added little value to CVD risk prediction
models containing traditional risk factors [25]. Regarding the
lower end of the HbA1c distribution both J-shaped [4,6,25] and no
relations [26] to all-cause mortality have been found. The studies
are not easily comparable, however, as a variety of cut-off levels
were applied.
The prognostic value of HbA1c in CAD patients without diabetes
has not been extensively evaluated. Prior studies, including patients
with acute coronary syndrome [8,9,27], showed that elevated levels
predicted increased risk of all-cause mortality. One of these cohorts
also demonstrated associations of elevated HbA1c levels to CVDe
and cancermortality. However, patients with newly diagnosed type
2 diabetes were not excluded from the study population [27],
which may explain the discordance from our results.
4.3. Interpretation of ﬁndings
HbA1c has low intra-, but high inter-individual variability and a
number of non-glycemic determinants [28,29]. Heritability of
HbA1c levels may be in the range of 40e60% [29], but genetic
variants associated with HbA1c levels among patients without
diabetes, have not been found to inﬂuence mortality [30]. In
addition to glucose concentrations, HbA1c levels can be affected by
conditions associated with changes in erythrocyte life span, like
hemoglobinopathies, vitamin B12 or iron deﬁciencies, liver or
kidney disease [31,32]. In addition, HbA1c valuesmay be reduced as
a consequence of heavy alcohol consumption [33].with suspected coronary artery disease. The association between glycated hemoglobin
ession. The simple model (left panel) is adjusted for age and gender. The multivariate
signiﬁcantly stenosed coronary arteries (0e3), left ventricular ejection fraction, revas-
rtery bypass graft surgery), previous acute myocardial infarction, estimated glomerular
treatment with statins and aspirin. The solid lines denote hazard ratios and the shaded
al lines denote values of 5.0% and 5.7%.
E.W. Rebnord et al. / Atherosclerosis 240 (2015) 115e120 119In the present cohort, levels of hemoglobin, cobalamin, liver
enzymes and eGFR were basically equally distributed across cate-
gories of HbA1c, and adjustment for these variables had only minor
effects on the risk estimates. In addition, we found no association
between self-reported alcohol consumption and HbA1c. Hence, in
our cohort of clinically stable CAD patients, with a low frequency of
other co-morbidities, glycemia is probably the main determinant of
HbA1c levels.
According to the most recent diagnostic guidelines, an HbA1c
cut-off at 5.7% deﬁnes a pre-diabetic state [1]. Individuals with pre-
diabetes were found to have increased intima media thickness of
the carotids, an early marker of atherosclerosis [34]. Pre-diabetes
has also been associated with risk of diabetes development as
well as future microvascular, and macrovascular complications [5].
However, a substantial proportion of subjects classiﬁed with pre-
diabetes will regress to normo-glycemia [35]. It is currently not
established whether the increased CVD risk is conﬁned to the
subset that eventually develops overt diabetes mellitus [36].
Insulin resistance is a key pathophysiologic feature of pre-
diabetes [37], which is characterized by reduced insulin sensi-
tivity in hepatocytes and muscle cells, accompanied by increased
insulin secretion from the pancreas. According to prevailing the-
ories, insulin resistance and the compensatory hyperinsulinemia
promote hypertension and dyslipidemia, as well as a pro-
thrombotic and pro-inﬂammatory state [38]. Correspondingly, the
prevalence of pre-diabetes overlaps substantially with the meta-
bolic syndrome [39]. The frequent co-occurrence with other CVD
risk factors complicates the isolation of vascular effects from in-
termediate hyperglycemia in epidemiological studies [5]. Hence,
whether pre-diabetes per se is causally related to atherosclerosis
and its complications is still uncertain [5]. Interestingly, insulin
resistance may also be present in normo-glycemic patients [36],
and is shown to be particularly prevalent in individuals at high CVD
risk [36] and in patients with established CAD [38].
In the present cohort, we found no differences in BMI or levels of
lipoproteins and CRP across categories of HbA1c. There was only a
weak tendency towards a higher prevalence of hypertension in
patients with pre-diabetes, and elevated HbA1c levels were actu-
ally associated with less extensive CAD at coronary angiography.
Notably, however, risk estimates were similar in age and gender
adjusted as in multivariate analyses, suggesting that confounding
factors are unlikely to explain the lack of associations between
HbA1c levels and clinical outcomes.
A community based prospective study, showed an adverse
prognostic effect from the diagnosis of pre-diabetes, which was
related to subclinical myocardial damage, evaluated by cardiac
troponin T levels [40]. In the present cohort, however, baseline
troponin T values were similar across HbA1c categories in the non-
diabetic range. Notably, these results are in accordance with prior
cross-sectional ﬁndings [41].
The fact that HbA1c showed no relation to CVD prognosis in a
patient population without diabetes, but with a high burden of
other risk factors, adds to the evidence that moderate hyperglyce-
mia is not an independent mediator of atherosclerotic complica-
tions [5]. However, randomized clinical trials are needed to provide
deﬁnite answers to this question. Prior studies have indicated that
hypoglycemic agents can delay the conversion of pre-diabetes to
diabetes [42], but showed no effects on surrogate markers of
atherosclerosis [43]. However, earlier trials have not been sufﬁ-
ciently powered to determine any effect on long-term risk of clin-
ical CVD events [42].
Studies from the general population [4,6], as well among pa-
tients with diabetes [44] have demonstrated increased risk of
mortality among subjects with low HbA1c values, although it re-
mains unclear whether these associations partly reﬂected residualconfounding [45]. Similar ﬁndings were not apparent in the present
cohort. However, our study was not designed to detect potential
adverse prognostic implications from HbA1c levels in the overt
hypoglycemic range.
4.4. Strengths and limitations
The strengths of our work include its prospective design, the
large sample size and detailed description of patient characteristics
at baseline, as well as the thorough evaluation of clinical outcomes.
As in any observational study, we cannot exclude the possibility of
unmeasured confounders. Neither can we rule out that some
under-reporting of clinical outcomes may have occurred, since the
collection of end-points was based on registry data. However, we
do not suspect that any misclassiﬁcation differed according to
HbA1c levels.
Blood samples were stored at 80 C, and HbA1c concentrations
were analyzed in samples that had been thawed twice. Notably,
however, HbA1c measurements were shown to be highly reliable for
up to 18 years of storage at 70 C [46], and levels were stable even
after several thawingefreezing cycles [47]. In the present study,
HbA1c values were only determined at baseline, but repeated ana-
lyses of HbA1c does not seem to improve CVD prediction beyond a
single measurement for individuals without diabetes [48].
In addition to being classiﬁed based on HbA1c levels, pre-
diabetes can be diagnosed from fasting glucose concentrations or
oral glucose tolerance tests [1]. Unfortunately, thesemeasures were
not available for our study population. Hence, we were not able to
compare the prognostic implications from different deﬁnitions of
pre-diabetes [49].
All the included patients underwent elective coronary angiog-
raphy for suspected stable CAD, and the majority received medi-
cations for CVD risk reduction, including aspirin and statins.
Consequently, our ﬁndings may not necessarily be generalizable to
other patient groups or to healthy individuals. Racial disparities
regarding HbA1c values have been reported [50]. As our cohort
consists almost exclusively of Caucasians, our results are unlikely to
be confounded by ethnicity, but may not necessarily apply to non-
Caucasian populations.
5. Conclusion
In a large cohort of suspected SAP patients without diabetes,
there were no overall associations between HbA1c and long-term
risk of coronary events or mortality. Thus, HbA1c measurements
appear to have a limited value for clinical risk evaluation of such
patients. Moreover, our data add to prior works questioning an
independent role of intermediate hyperglycemia in mediating
acute atherosclerotic complications.
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